Algernon Pharmaceuticals Stock Return On Equity
| AGNPF Stock | USD 0.06 0 3.16% |
Algernon Pharmaceuticals fundamentals help investors to digest information that contributes to Algernon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Algernon OTC Stock. The fundamental analysis module provides a way to measure Algernon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Algernon Pharmaceuticals otc stock.
Algernon |
Algernon Pharmaceuticals OTC Stock Return On Equity Analysis
Algernon Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Algernon Pharmaceuticals Return On Equity | -1.09 |
Most of Algernon Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Algernon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Algernon Pharmaceuticals has a Return On Equity of -1.0923. This is 95.44% lower than that of the Healthcare sector and 97.0% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.
Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Algernon Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.53 | |||
| Current Valuation | 3.03 M | |||
| Shares Outstanding | 2.41 M | |||
| Shares Owned By Insiders | 1.70 % | |||
| Shares Owned By Institutions | 14.73 % | |||
| Price To Book | 1.02 X | |||
| EBITDA | (6.02 M) | |||
| Net Income | (6.05 M) | |||
| Cash And Equivalents | 872.84 K | |||
| Cash Per Share | 0.44 X | |||
| Current Ratio | 1.16 X | |||
| Book Value Per Share | 1.86 X | |||
| Cash Flow From Operations | (2.91 M) | |||
| Earnings Per Share | (2.28) X | |||
| Beta | 0.32 | |||
| Market Capitalization | 3.96 M | |||
| Total Asset | 8.14 M | |||
| Net Asset | 8.14 M |
About Algernon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Algernon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Algernon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Algernon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Algernon OTC Stock
Algernon Pharmaceuticals financial ratios help investors to determine whether Algernon OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Algernon with respect to the benefits of owning Algernon Pharmaceuticals security.